Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Key PointsEli Lilly's high valuation could limit the stock's future returns.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.